Schedule 13G ownership disclosure

Amylyx Pharmaceuticals Inc

Common Stock, $0.0001 par value per share · CUSIP: 03237H101

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • TCG Crossover GP II, LLC

    Shares: 6,243,812 · Class: 5.7%

  • TCG Crossover Fund II, L.P.

    Shares: 6,243,812 · Class: 5.7%

  • Chen Yu

    Shares: 6,243,812 · Class: 5.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-054741
Form type
SCHEDULE 13G/A
Filer
Amylyx Pharmaceuticals, Inc.
CIK
CIK 1658551
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub